Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia
Authors:
- Yuriy SirenkoYSYuriy Sirenko
- On behalf of the PERSPECTIVA Study GroupOGOn behalf of the PERSPECTIVA Study Group
- Ganna RadchenkoGRGanna Radchenko
- 2 February 2017
- journal article
- research article
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 24 (1) , 85-93
Abstract
Introduction Several lines of research indicate that statins can lower blood pressure (BP) independently of their lipid-lowering effects when used as monotherapy and in combination with antihypertensive agents. Aim This short-term, open-label study examined whether statin therapy had a synergistic effect on the BP-lowering efficacy of perindopril/amlodipine in a subgroup of patients in the PERSPECTIVA study with concomitant hypertension and hypercholesterolemia, with or without statin at baseline. Methods The PERSPECTIVA study recruited 732 adults with untreated or uncontrolled hypertension. This subgroup analysis of PERSPECTIVA included 587 patients with concomitant hypertension and hypercholesterolemia (mean age 56.7 years) of whom 226 were receiving a statin at baseline (statin [+] group) and 361 were not (statin [−] group). All patients received treatment with single-pill combination perindopril/amlodipine at a dose of 5/5, 10/5 or 10/10 mg/day. The study duration was 60 days with follow-up visits for BP monitoring at 7, 15, 30 and 60 days. Results At day 60, BP control (<140/90 mmHg) was significantly greater in the statin [+] vs statin [−] group: 73 vs 64% respectively (+14%, P < 0.05). In the statin [+] group, the single-pill perindopril/amlodipine combination significantly reduced BP in patients previously untreated (n = 18), or treated with monotherapy (n = 97), dual therapy (n = 93), or triple therapy (n = 18): −38.8/−20.0, −39.1/−20.1, −38.0/−19.4, −39.9/−18.3 mmHg respectively (P < 0.001 vs baseline BP). The greatest BP reductions were observed in the first 7 days. Treatment was well tolerated with a similar rate of adverse events in the statin [+] group (0.9%) vs the statin [−] group (2.5%). Conclusion BP control rates in patients with uncontrolled hypertension and concomitant hypercholesterolemia are significantly improved with a treatment regimen that combines perindopril/amlodipine with statin therapy, regardless of previous antihypertensive therapy. This subanalysis of the PERSPECTIVA study supports the synergistic BP-lowering effect of statins and perindopril/amlodipine.Keywords
Funding Information
- Servier Ukraine
This publication has 50 references indexed in Scilit:
- Hypertension Control and Cardiometabolic Risk: A Regional PerspectiveCardiology Research and Practice, 2012
- Pleiotropic and Lipid and #8211;lowering Effects of Statins in HypertensionMateria Socio Medica, 2012
- Combination Therapy in HypertensionThe Journal of Clinical Hypertension, 2010
- Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trialBMJ, 2010
- Do Statins Reduce Blood Pressure?Hypertension, 2007
- Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patientsAmerican Heart Journal, 2005
- Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular riskThe Lancet, 2005
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Improvement of Nitric Oxide–Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion FormationArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998